SCHEMBL2011983

SCHEMBL2011983

Fc1ccccc1Cc1nsc(N2CCCNCC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 2/20 0.43
HTR2C P28335 1/20 0.43
HTR1A P08908 3/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
HTR6 P50406 4/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
CHRNB2 P17787 2/20 0.38
CHRNA4 P43681 2/20 0.38
SLC6A3 Q01959 1/20 0.37
PRMT5 O14744 1/20 0.36
NCF1 P14598 1/20 0.36
CSNK1A1 P48729 1/20 0.36
ALDH1A1 P00352 1/20 0.35
PIM1 P11309 1/20 0.35
PIM3 Q86V86 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2006686 0.95 HTR2B (0.46) HTR2BHTR2CHTR1ASLC6A2SLC6A4
SCHEMBL2009208 0.86 LMNA (0.43) HTR2BHTR2CHTR1ASLC6A2SLC6A4
SCHEMBL2003762 0.83 HTR7 (0.45) HTR2BHTR2CSLC6A2SLC6A4HTR6
SCHEMBL2005372 0.83 CETP (0.47) HTR2BHTR2CHTR1AHTR6KDM4E
SCHEMBL3066582 0.81 DPP4 (0.45) HTR6MAPTALDH1A1SMN1; SMN2
SCHEMBL2008248 0.81 HTR2B (0.43) HTR2BHTR2CHTR1AHTR6ALDH1A1
SCHEMBL2005879 0.80 LMNA (0.47) HTR2BHTR2CHTR1ASLC6A2SLC6A4
SCHEMBL2008099 0.79 HTR2B (0.45) HTR2BHTR2CHTR1AHTR6PRMT5
SCHEMBL2007117 0.79 HTR6 (0.40) HTR2BHTR2CHTR1ASLC6A2SLC6A4
SCHEMBL2007838 0.77 SOS1 (0.47) NCF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed
EP-2094677-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV Remynd (BE) 2009-09-02 EP disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP HTR2B 2061/4885HTR2C 1846/4885HTR1A 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.